Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
复制标题
DOI：
10.1182/blood.v60.2.454.bloodjournal602454
复制
发表时间：
1982-08
期刊：
影响因子：
20.3
通讯作者：
Jerome W. Yates;O. Glidewell;P. Wiernik;Cooper;D. Steinberg;H. Dosik;R. Levy;C. Hoagland;P. Henry;A. Gottlieb;C. Cornell;J. Berenberg;JL Hutchison;P. Raich;N. Nissen;R. Ellison;R. Frelick;G. James;G. Falkson;R. Silver;F. Haurani;Mark A. Green;E. Henderson;L. Leone;J. Holland
中科院分区：
文献类型：
--
作者：
Jerome W. Yates;O. Glidewell;P. Wiernik;Cooper;D. Steinberg;H. Dosik;R. Levy;C. Hoagland;P. Henry;A. Gottlieb;C. Cornell;J. Berenberg;JL Hutchison;P. Raich;N. Nissen;R. Ellison;R. Frelick;G. James;G. Falkson;R. Silver;F. Haurani;Mark A. Green;E. Henderson;L. Leone;J. Holland
对柔红霉素(DNR)30或45 mg/平方米或阿霉素(ADM)30或45毫克/平方米或阿霉素(ADM)30毫克/平方米的相对疗效和毒性进行随机比较，结果表明，结果取决于蒽环类药物、剂量和患者年龄。DNR45在诱导60岁以下患者完全缓解(CR)方面明显优于DNR30或ADM30(分别为72%、59%、58%)。在60岁以上的患者中，DNR30较DNR45或ADM30诱导CR更好(分别为47%、31%、35%)。在年龄、剂量和蒽环类药物组中，诱导死亡率有相应的变化。阿霉素对胃肠道的毒性明显强于柔红霉素。完全缓解的持续时间与维持治疗的周期无关，与患者的年龄、诱导过程中使用的蒽环类药物的剂量或选择无关，也与维持疗程是每4周还是每8周进行一次无关。
A randomized comparison of the relative efficacy and toxicity of daunorubicin (DNR) at 30 or 45 mg/sq m or adriamycin (ADM) at 30 mg/sq m, given on the first 3 days of a 7-day continuous infusion of cytosine arabinoside (ara-C) at 100 mg/sq m/day, shows the outcome to be dependent on anthracycline, dose, and patient age. DNR 45 is significantly better than DNR 30 or ADM 30 for inducing complete remissions (CR) in patients younger than 60 yr, (72%, 59%, 58% CRs, respectively). DNR 30 is better than DNR 45 or ADM 30 for inducing CR in patients older than 60 yr (47%, 31%, 35%, respectively). There was a corresponding shift in the induction mortality for the age, dose, and anthracycline groups. Adriamycin was significantly more toxic to the gastrointestinal tract than daunorubicin. The duration of complete remission, with cyclic courses of maintenance therapy, was independent of the patient's age, the dose, or choice of anthracycline used in induction, and of whether the maintenance courses were given every 4 wk or every 8 wk.